Cohance Lifesciences Profits Plummet 87% Amid FDA Woes, Guides for Revenue Decline

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAditi Singh|Published at:
Cohance Lifesciences Profits Plummet 87% Amid FDA Woes, Guides for Revenue Decline
Overview

Cohance Lifesciences (formerly Suven Pharma) reported a brutal Q3 FY26, with Adjusted PAT plunging 87.3% YoY to ₹21.1 Cr and margins collapsing. Revenue fell 19.5% YoY. The company cited an FDA Warning Letter at its Nacham facility, causing ₹55 Cr shipment deferrals and disruptions. With FY26 declared a "transition year" and revised guidance predicting an "early-to-mid double-digit decline" in revenue, recovery is anticipated from FY27, driven by R&D pipeline conversions and capacity expansions. Despite the downturn, the company maintained a net cash positive position and reduced borrowings.

📉 The Financial Deep Dive

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has announced a stark financial downturn for its third quarter and nine months ended December 31, 2025. The company characterized FY26 as a "transition year," with a revised revenue guidance now pointing to an "early-to-mid double-digit decline." A return to revenue growth is, however, anticipated in FY27.

Quarterly Performance (Q3 FY26 vs. Q3 FY25):

  • Revenue: Operations saw a significant 19.5% year-on-year (YoY) decline, falling to ₹5,445.50 Cr.
  • Adjusted EBITDA: A substantial 67.7% YoY drop to ₹847 million (₹84.7 Cr) was recorded, with EBITDA margins contracting severely from 38.8% to 15.6%.
  • Adjusted PAT: Profit After Tax plummeted by a staggering 87.3% YoY to ₹211 million (₹21.1 Cr), with margins shrinking from 24.6% to a mere 3.9%.

Nine-Month Performance (9M FY26 vs. 9M FY25):

  • Revenue: Operations decreased by 6.7% YoY to ₹16,494.30 Cr.
  • Adjusted EBITDA: Fell 43.4% YoY to ₹3,477 million (₹347.7 Cr), and margins contracted to 21.1% from 34.8%.
  • Adjusted PAT: Declined 61.4% YoY to ₹1,513 million (₹151.3 Cr), with margins at 9.2% compared to 22.2%.
  • Gross Margins: Showed improvement YoY, rising to 72.8% from 70.8%, attributed to product mix and acquisition consolidation.

Exceptional Items and Operational Impact:

Exceptional items for 9M FY26 amounted to ₹130 million (₹13 Cr), including one-time restructuring costs from mergers and actuarial impacts related to new labour codes. For Q3 FY26, exceptional items were ₹49 million (₹4.9 Cr), primarily due to gratuity impact.

A critical operational challenge arose at the Nacham facility, which experienced temporary disruptions and shipment deferrals of approximately ₹55 Cr due to a US FDA Warning Letter. Remediation actions are reportedly underway.

Outlook and Strategy:

Management's focus for FY26 is on stabilizing leadership, strengthening execution, and advancing commercial conversions. The recovery strategy hinges on converting RFPs (Requests for Proposals), commissioning new capacities, and scaling up commercially. Key growth platforms like Antibody-Drug Conjugates (ADC) and Oligonucleotides remain robust. A USD 10 million expansion in the US for ADC supply up to Phase 2b by FY27 is in progress, and the Nacham building-block facility for oligonucleotides is nearing operationalisation. The Specialty Chemicals and API+ segments exhibit mixed performance, with regulatory delays impacting the former and shipment adjustments affecting the latter.

Financial Position:

The company maintained a healthy net cash positive position of ₹1,759 million (₹175.9 Cr) as of December 31, 2025. Free cash flow generated for 9MFY26 was ₹1,750 million (₹175 Cr), with capital expenditure of ₹1,610 million (₹161 Cr) deployed primarily for capacity expansions. Total borrowings were reduced to ₹2,560 million (₹256 Cr).

Corporate Actions:

The company recently completed mergers with Casper Pharma Private Limited and the erstwhile fellow subsidiary Cohance Lifesciences Limited. It also acquired a 56% stake in NJ Bio Inc., signaling a strategic push for growth and consolidation.

🚩 Risks & Forward View

Investors must closely monitor the resolution of the US FDA Warning Letter at the Nacham facility, as further delays or stringent actions could significantly impact future shipments and revenue. Regulatory timing delays in the Specialty Chemicals segment also pose a risk. The primary focus in the near term will be on the company's ability to execute its recovery strategy, particularly in converting RFPs and scaling up commercial operations. The successful commissioning and ramp-up of new capacities for ADC and Oligonucleotides will be crucial indicators for the anticipated FY27 turnaround.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.